Need for Extemporaneous Formulations in Pediatric Patients

The number of new drugs being marketed in the U.S. appears to be increasing; 27 new agents reached the market during the first 6 months of 1998. However, most new drugs are not labeled for certain populations e.g. infants and children. It has been estimated that over 80% of the drugs approved by the FDA have not been labeled for use in infants and children. Only 5 of the 80 drugs most commonly used in newborn infants were labeled for use in this population. When a drug is not approved by the FDA for infants and children, it is usually not available in a suitable dosage form for the pediatric population.

“Off label” use of drugs is common in pediatric patients. In fact, it would be unethical to not use a potentially better therapy, just because it is not yet approved by the FDA. In such cases, the alternatives are to refuse or delay access to a promising drug or provide an extemporaneous formulation to the patient. Examples of some orally used medications not available commercially in liquid dosage forms appear in Table 1. Extemporaneous formulations have an important role especially in infants and young children (below 6 years of age), who are unable to swallow tablets or capsules. In addition, these patients require doses based on body weight, and fixed doses in tablets or capsules intended for adults cannot be given to infants and children. For example, captopril is available only as tablets containing 12.5 mg, 25 mg, 50 mg and 100 mg each.

The dose in an infant is 0.1-0.3 mg/kg; thus, the dose in a patient weighing 5 kg could be 1 mg. The only practical solution to this problem would be to prepare a liquid (e.g., 1 mg/mL) to provide the desired dose. However, the stability of captopril in aqueous medium was unknown for several years after its initial use began. In fact, the manufacturer indicated that it underwent oxidation in the presence of water. Thus, powder packets of captopril were prepared with lactose, to be administered by the caregiver just prior to the dose. The powders are time consuming and cumbersome to make, and errors may occur in preparing and administering the doses. Our efforts in preparing captopril solution in the presence of water and ascorbic acid (as antioxidant) led to a liquid formulation stable for at least 8 weeks. (See Table 2, next page)

This formulation is now routinely used in infants and young children with hypertension or congestive heart failure at our institution.

Intravenous drugs not approved for infants and young children are often not available in appropriate (low) concentrations for accurate and precise measurement of small doses. For example, phenobarbital is commercially available at a concentration of 65 mg/mL. The dose in an infant may be 2.5 mg/kg to be given every 12 hours. Thus, the dose in a premature infant weighing 1 kg would be 2.5 mg and 0.038 mL would need to be measured to administer each dose. Errors may occur in measuring doses less than 0.1 mL. Such errors with potent drugs like morphine and digoxin have led to intoxication in pediatric patients. One solution would be to dilute these concentrated drugs intended

TABLE 1. EXAMPLES OF DRUGS NOT AVAILABLE IN LIQUIDS

- Acetazolamide
- Amlodipine
- Captopril
- Dapsone
- Granisetron
- Lamotrigine
- Levofloxacin
- Omeprazole
- Rifampin
- Spironolactone/hydrochlorothiazide
- Topiramate
- Vigabatrin
- Allopurinol
- Azathioprine
- Clonazepam
- Enalapril
- Indinavir
- Levodopa/carbidopa
- Mexiletine
- Propylthiouracil
- Sertraline
- Ursodiol
- Zidovudine/lamivudine
- Amiodarone
- Caffeine
- Clonidine
- Gabapentin
- Isradipine
- Nifedipine
- Pyrazinamide
- Spironolactone
- Sumatriptan
- Verapamil

Milap C. Nahata, M.S., Pharm.D., Professor of Pharmacy and Pediatrics, The Ohio State University, Wexner Institute for Pediatric Research, and Children’s Hospital Columbus, OH.
The pH of Ora-Plus is about 4.4 while that of 1% methylcellulose suspension (Ora-Plus, Paddock Laboratories, Minneapolis, MN) is nearly 6.8. We routinely mix the suspending agent with equal volume of commercially available simple syrup or Ora Sweet (sugared or sugar free). Flavors and preservatives may be added, as necessary. The commercially available intravenous drugs are normally diluted in sterile or bacteriostatic water for injection or 0.9% sodium chloride injection.

The physical and chemical stability of drugs in extemporaneous formulations is determined at clinically simulated conditions e.g., desired drug concentration, storage container and temperature, and duration of use. For example, about an ounce of the prepared formulation is stored in each of 10 plastic prescription bottles. Five bottles are stored at 4°C in a refrigerator and five at 25°C. Small aliquots are collected and normally studied on day 0 (soon after preparation) and on days 3, 7, 14, 28, 56, 70 and 91 during storage. On each study day, the physical stability is assessed by visual appearance against a white and black background to rule out any changes in color and appearance; odor is also evaluated. The chemical stability is determined by measuring the concentration of the drug using an accurate, specific, reproducible, and stability-indicating analytical method e.g. high performance liquid chromatographic technique on each day of study. The pH is also measured on each study day.

The stability-indicating nature of the method is confirmed by subjecting samples of the extemporaneous formulation to extremes of temperature by heating, and to low and high pH by subjecting samples of the extemporaneous formulation to extremes of temperature by heating, and to low and high pH by mixing with an acid and a base. The degradation products should not interfere with the measurement of the drug for a method to be stability-indicating. The drug is considered stable, if its physical characteristics have not changed and its concentration has remained above 90% of the initial concentration.

The palatability of an extemporaneous formulation should also be assessed. A palatable formulation is more likely to improve compliance and minimize spillage during administration of doses. A 5-point scale or facial expressions are used to assess palatability of formulations in pediatric patients. Sterility and pyrogen tests are done by using USP methods.

In general, pharmacokinetics, pharmacodynamics, efficacy and

---

**TABLE 2**

**GENERIC NAME:** Captopril  
**DOSED FORM:** oral solution  
**MADE FROM:** tablets  
**CONCENTRATION:** 1 mg/mL  
**STABILITY:** 56 d  
**STORE:** refrigerate  
**LABEL:** shake well  
* Captopril tablets 50 mg, 2 tablets  
* Sodium ascorbate injection or ascorbic acid tablets 500 mg,  
* Distilled water qs ad 100 mL  
**Instructions:** Allow 2 tablets of captopril 50 mg to dissolve in 50 mL of water in a graduate. Add the contents of a 500-mg ampul of sodium ascorbate or a 500-mg ascorbic acid tablet to the mixture and qs with distilled water. Shake well to disperse. Do not filter.  
**Note:** A sulfur-like odor is not indicative of captopril degradation.  
Nahata MC, Hipple If, Morosco RS. Stability of captopril in their liquid dosage forms. Am J Hosp Pharm 1994; 51: 95-6  
Reprinted by permission of author.

**TABLE 3**

**GENERIC NAME:** Methylcellulose  
**DOSED FORM:** oral suspension  
**MADE FROM:** powder  
**CONCENTRATION:** 1%  
**STABILITY:** 6 mo  
**STABILITY REFERENCE:** experience  
* Methylcellulose powder 4000cps 10g,  
* Methylparaben 200mg,  
* Propylparaben 100mg,  
* Purified water USP qs 1000mL  
**Instructions:** Heat 200 mL of purified water to boiling. Add the parabens and mix well. Wet the methylcellulose powder and add it. Allow to stand for 15 minutes, then remove from heat. Then qs with cold purified water while mixing well with a magnetic stirrer. Keep mixing until a clear, homogeneous solution results.  
Reprinted by permission of author.
safety studies are rarely conducted with extemporaneous formulations. The pharmacokinetics can be somewhat different for a drug in an extemporaneous versus a commercially available formulation. The tablets and capsules containing sustained or timed release drug products should not be used to prepare liquid dosage forms, as the sustained release property may be lost in preparing an extemporaneous formulation. Since performance of pharmacokinetic studies is expensive and limited resources are available for these studies, patients receiving a new extemporaneous formulation should be carefully monitored to document efficacy and safety of the drug. Excessive use of sorbitol or propylene glycol should be avoided as the former can lead to diarrhea and the latter to hyperosmolality.10

NEW REGULATIONS

The FDA has issued new regulations requiring manufacturers to conduct pediatric studies and seek labeling for new drugs in pediatric patients. However, the requirement can be waived for a number of reasons including difficulty in developing a pediatric formulation, as long as “reasonable efforts” were made.11 It is unclear what would be sufficient as “reasonable efforts.”

Small size of the pediatric market for most drugs is perhaps the leading reason for the lack of investment in drug development for this population by the industry. The FDA will provide incentives to the industry (6 month extension of exclusivity and waiver of fees for the supplemental new drug application) for pediatric drug development.12 This may lead to increased availability of pediatric formulations of new drugs; however, extemporaneous formulations would still be needed for the generic drugs and for marketed drugs of little interest to the sponsor. In addition, the potential use of a new drug in infants and children may not be apparent at the time of seeking initial approval for adults.

The FDA Modernization Act of 1997 (FDAMA) also has provisions for bulk drug substances. Effective November 21, 1998, FDA must develop and publish regulations to address various aspects of pharmacy compounding. The compounding law stipulates that the bulk substances used in compounding should be 1) components of an FDA-approved drug product; 2) in a USP or National Formulary monograph; or 3) included in a list developed by the FDA, with the input from its Pharmacy Compounding Advisory Committee.12 (Table 4, next page) A request for inclusion of substances on this list was made.13 It is unclear what may happen if the list is incomplete and whether the efficacy and safety of the substances would have to be assured before placing them on the list.

SUMMARY

Extemporaneous drug formulations play an important role for pediatric patients. As an example, many frequently used drugs are available only as tablets or capsules, but not in suitable liquid dosage forms. Thus, such medications cannot be used in patients unable to swallow tablets or capsules. Pharmacists must extemporaneously compound these medicines. However, stability data are often lacking for these products. In such cases, physical and chemical stability must be determined using clinically simulated conditions (e.g., concentration, storage temperature and containers) for the drugs. Palatability and microbiological studies also may be needed in certain situations. Pharmacokinetics/pharmacodynamics, efficacy and safety studies are usually not done, but may be necessary in some cases. Recent regulations of the U.S. Food and Drug Administration were proposed to increase the labeling of new drugs for pediatric patients. The implementation of these regulations should also increase the availability of suitable dosage forms of some new drugs. It should be realized, however, that the need for extemporaneous formulations of many existing drugs and some new ones will continue. Thus, pharmacists have a unique role in compounding these medicines for use in pediatric patients.

Increased funding by the universities, government, industry and foundations would be required to develop stable formulations, conduct studies, and publish results. Joint efforts by various groups including practitioners, academia, industry, government and professional associations is required for making extemporaneous formulations accessible to the most vulnerable populations e.g. infants, young children and the elderly unable to take commercially available dosage forms.

REFERENCES


**TABLE 4:**
Pharmacy Compounding Advisory Committee Center for Drug Evaluation and Research.

<table>
<thead>
<tr>
<th><strong>Chair</strong></th>
<th><strong>Executive Secretary</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Randy P. Juhl, Ph. D. 09/30/02</td>
<td>Jayne E. Peterson, R.Ph., J.D.</td>
</tr>
<tr>
<td>School of Pharmacy, Office of the Dean, University of Pittsburgh, 1103 Salk Hall, Pittsburgh, Pennsylvania 15261</td>
<td>Advisors and Consultants Staff, 5600 Fishers Lane, Rockville, Maryland 20857</td>
</tr>
<tr>
<td></td>
<td>(301) 827-6766 Fax: (301) 827-6776 Email: <a href="mailto:Petersonj@cder.fda.gov">Petersonj@cder.fda.gov</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Members</strong></th>
<th><strong>Members</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Judith Martin Rifiee, R. Ph. 09/30/00</td>
<td>William J. Rodriguez, M.D., Ph.D. 09/30/00</td>
</tr>
<tr>
<td>1639 N. W. 11th Road, Gainesville, Florida 32610</td>
<td>Chairman, Department of Infectious Diseases, Children’s National Medical Center, 111 Michigan Avenue, N.W., Washington, D.C. 20010</td>
</tr>
<tr>
<td>Tony Welder, R. Ph. 09/30/00</td>
<td>Loyd V. Allen Jr., Ph. D. 09/30/01</td>
</tr>
<tr>
<td>Dakota Pharmacy, Post Office Box 835, 717 East Main Avenue, Bismarck, North Dakota 58501</td>
<td>Editor-In-Chief, International Journal of Pharmaceutical Compunding, 122 North Bryant, Edmond, Oklahoma 73034</td>
</tr>
<tr>
<td>Carmen A. Catizone, M.S., R. Ph. 09/30/01</td>
<td>Elizabeth I. McBumney, M.D. 09/30/01</td>
</tr>
<tr>
<td>National Association of Boards of Pharmacy, 700 Busse Highway, Park Ridge, Illinois 60068</td>
<td>Clinical Professor, Louisiana State University School of Medicine, P.O. Drawer 2179, 1051 Gausse Boulevard, Suite 460, Slidell, Louisiana 70458</td>
</tr>
<tr>
<td>Sarah L. Sellers, Pharm.D. 09/30/01</td>
<td>Garnet E. Peck, Ph.D. 09/30/02</td>
</tr>
<tr>
<td>316 Beech Cove Dr, Grimesland, NC 27837</td>
<td>Department of Industrial and Physical Pharmacy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907</td>
</tr>
<tr>
<td>Christopher T. Rhodes, Ph.D. 09/30/02</td>
<td>William J. Rusho, R.Ph. 09/30/02</td>
</tr>
<tr>
<td>Professor of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881</td>
<td>Professor of Pharmacy Practice, Department of Pharmacy Services, University of Utah Hospitals and Clinics, 50 North Medical Drive, room A050, Salt Lake City, Utah 84132</td>
</tr>
<tr>
<td>Lawrence Trissel, F.A.S.H. P 09/30/02</td>
<td>Industry Representative (Non-voting)</td>
</tr>
<tr>
<td>Director, Clinical Pharmaceutics Research Program, Division of Pharmacy, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Room B1-4302, Houston, Texas 77030</td>
<td>David Liebman, R. Ph. 09/30/00</td>
</tr>
<tr>
<td>Consumer Representative</td>
<td>Kaye’s Pharmacy, 6913 Belair Road, Baltimore, Maryland 21206</td>
</tr>
<tr>
<td>Rose-Ellen M. Hope, R. Ph. 09/30/02</td>
<td>1355 S. Water, Silverton Oregon 97381</td>
</tr>
<tr>
<td>50 North Medical Drive, room A050, Salt Lake City, Utah 84132</td>
<td>Industry Representative (Non-voting)</td>
</tr>
<tr>
<td>Industry Representative (Non-voting)</td>
<td>David Liebman, R. Ph. 09/30/00</td>
</tr>
<tr>
<td>Joan M. LaFollette, R. Ph. 09/30/01</td>
<td>Kaye’s Pharmacy, 6913 Belair Road, Baltimore, Maryland 21206</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company, Director, Worldwide Regulatory Affairs- CMC, 311 Pennington-Rocky Hill Road, Room 306, Pennington, New Jersey 08534</td>
<td>311 Pennington-Rocky Hill Road, Room 306, Pennington, New Jersey 08534</td>
</tr>
</tbody>
</table>
BIBLIOGRAPHY-STABILITY STUDIES OF EXTEMPOREANOUSLY PREPARED ORAL FORMULATIONS

Baclofen - Am J Health-Syst Pharm. 1996; 53: 2179-84
Captopril - Am J Health-Syst Pharm. 1996; 53: 2179-84
Diltiazem HCl - Am J Health-Syst Pharm. 1996; 53: 2179-84
Diprydamole - Am J Health-Syst Pharm. 1996; 53: 2179-84
Flecainide Acetate - Am J Health-Syst Pharm. 1996; 53: 2179-84
Ganciclovir - Contact company (Roche, 800-562-6367) for data - Am J Health-Syst Pharm. 1999; 57(17): 1738-41
Itraconazole - J Ped Pharm Prac 1998; 3: 115-8
Labetolol HCl - Am J Health-Syst Pharm. 1996; 53: 2304-9
Lamotrigine - AM J Health-Syst Pharm. 1999; 56: 240-2
Levofloxacin - AMJ Health-Sys Pharm. 1999; 56: 2316-18
Metolazone - Am J Health-Syst Pharm. 1996; 53: 2073-8
Metronidazole - Am J Health-Syst Pharm. 1996; 53: 2073-8
Mycophenolate Mofetil - Am J Health-Syst Pharm. 1999; 56: 2224-6
Ondasetron - Am J Health-Syst Pharm. 1994; 51: 806-9
Procainamide HCl - Am J Health-Syst Pharm. 1996; 53: 2073-8
Rifabutin - Am J Health-Syst Pharm. 1999; 56: 333-6
Spironolactone - Am J Health-Syst Pharm. 1996; 53: 2073-8
Ursodiol - Am J Health-Syst Pharm. 1997; 54: 1401-4
Valacyclovir - AM J Health-Syst Pharm. 1999; 56: 1957-60
Verapamil HCl - Am J Health-Syst Pharm. 1996; 53: 2304-9

Studies use either Ora-Sweet®, Ora-Plus®, or Ora-Sweet SF® alone or in combination.
When swallowing a tablet is a problem...

A Spoonful from Paddock Helps the Medicine Go Down

The Paddock Solid-to-Liquid Solution

Paddock Laboratories is the leading pharmaceutical supplier of compounding actives, vehicles and professional support.

When compounding oral liquids, Paddock’s Ora-Plus® and Ora-Sweet® provide the solution.

Compounding with Confidence

Over 30 formulations extemporaneously compounded with Ora-Plus and Ora-Sweet have been studied and tested.

These formulations and stability studies are available to provide you with an extra measure of confidence to “help the medicine go down”.

For a copy of these stability studies, please call 1-800-328-5113 or visit www.paddocklabs.com.

Extemporaneous Formulations and Stability Studies Available For:

- Acetazolamide
- Allopurinol
- Alprazolam
- Azathioprine
- Baclofen
- Bethanechol
- Captopril
- Chloroquine Phosphate
- Cisapride
- Clonazepam
- Diltiazem HCl
- Dipyridamole
- Enalapril Maleate
- Flecainide Acetate
- Flucytosine
- Hydralazine HCl
- Ketoconazole
- Labetalol
- Metolazone
- Metoprolol Tartrate
- Metronidazole
- Procainamide
- Pyrazinamide
- Quinidine Sulfate
- Rifampin
- Spironolactone
- Spironolactone/HCTZ
- Tetracycline HCl
- Verapamil HCl